BNP Paribas Financial Markets Buys 2,597 Shares of Mesoblast Limited (NASDAQ:MESO)

BNP Paribas Financial Markets boosted its stake in shares of Mesoblast Limited (NASDAQ:MESO) by 86,566.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,600 shares of the company’s stock after purchasing an additional 2,597 shares during the quarter. BNP Paribas Financial Markets’ holdings in Mesoblast were worth $51,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Strategic Financial Concepts LLC bought a new position in Mesoblast during the fourth quarter worth $2,744,000. Quadrant Capital Group LLC boosted its position in Mesoblast by 41.1% during the fourth quarter. Quadrant Capital Group LLC now owns 6,496 shares of the company’s stock worth $129,000 after purchasing an additional 1,891 shares during the period. LPL Financial LLC boosted its position in Mesoblast by 7.7% during the fourth quarter. LPL Financial LLC now owns 38,882 shares of the company’s stock worth $770,000 after purchasing an additional 2,795 shares during the period. Barclays PLC bought a new position in Mesoblast during the fourth quarter worth $38,000. Finally, Oaktree Fund Advisors LLC bought a new position in Mesoblast during the fourth quarter worth $949,000. 1.43% of the stock is owned by institutional investors.

Mesoblast Stock Performance

MESO opened at $10.55 on Wednesday. Mesoblast Limited has a fifty-two week low of $5.78 and a fifty-two week high of $22.00. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18. The stock has a fifty day moving average of $11.13 and a 200-day moving average of $13.97.

Analyst Ratings Changes

MESO has been the subject of a number of research analyst reports. Piper Sandler reaffirmed an “overweight” rating and set a $24.00 price objective (up from $15.00) on shares of Mesoblast in a research report on Friday, February 7th. Cantor Fitzgerald raised Mesoblast to a “strong-buy” rating in a report on Monday, March 31st. One research analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Mesoblast Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.